A randomized multicenter trial of neoadjuvant Taxotere [docetaxel] and Adriamycin [doxorubucin]/Cytoxan [cyclophosphamide] (AC): a biologic correlative study.

Trial Profile

A randomized multicenter trial of neoadjuvant Taxotere [docetaxel] and Adriamycin [doxorubucin]/Cytoxan [cyclophosphamide] (AC): a biologic correlative study.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 24 Jan 2012 Actual end date (1 Jan 2012 ) added as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Oct 2011 Actual patient no is 70 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top